Neuroendocrine Tumor ICD-10-CM Codes | 2023

What ICD-10 Codes are used for Neuroendocrine Tumor

ICD-10 codes are essential for accurately documenting and coding various medical conditions, including neuroendocrine tumors (NETs). Neuroendocrine tumors are a group of rare cancers that arise from cells of the endocrine (hormone-producing) and nervous systems. 

Here are the commonly used neuroendocrine tumors ICD-10 codes: 

• C25.0 - Malignant neoplasm of the head of the pancreas: This code is used for neuroendocrine tumors in the head of the pancreas. These tumors may cause symptoms related to the pancreas, such as abdominal pain, weight loss, and digestive issues.
• C25.4 - Malignant neoplasm of the endocrine pancreas: This code applies to neuroendocrine tumors specifically arising from the endocrine cells of the pancreas. These tumors can produce hormones, leading to various symptoms depending on the type of hormones released.
• C25.9 - Malignant neoplasm of pancreas, unspecified: This code is used when the specific location within the pancreas is not specified. It is a general code for malignant neoplasms of the pancreas and is often used when the exact site of the tumor is not known.
• C73 - Malignant neoplasm of the thyroid gland: This code is applicable when the neuroendocrine tumor is located in the thyroid gland. Neuroendocrine tumors of the thyroid can produce thyroid hormones, leading to symptoms like changes in metabolism and thyroid-related issues.
• C7A.0 - Islet cell tumor, malignant: This code is used for malignant islet cell tumors, a neuroendocrine tumor type. Islet cell tumors can be found in various organs, and their clinical presentation depends on the hormones they produce.
• C7B.00 - Malignant carcinoid tumor of the bronchus and lung, unspecified: This code treats malignant carcinoid tumors in the bronchus and lung that produce hormones causing breathing difficulties, wheezing, and flushing.
• D37.1 - Neoplasm of uncertain behavior of endocrine glands: This code is used for uncertain or unclear neuroendocrine tumors when malignancy potential is not well-determined.
• D3A.9 - Benign neoplasm of endocrine gland, unspecified: Benign neuroendocrine tumors can still cause symptoms based on location and hormone production but are generally less aggressive than malignant tumors.
• D3A.1 - Benign carcinoid tumor: Benign carcinoid tumors can produce hormones leading to symptoms like flushing and gastrointestinal issues.
• D3A.0 - Benign neoplasm of the stomach: Benign neuroendocrine tumors in the stomach may cause stomach-related symptoms like pain or discomfort.

Accurate coding of neuroendocrine tumors using ICD-10 codes is crucial for proper medical recordkeeping, billing, and facilitating research on these rare and diverse malignancies.

Which Neuroendocrine Tumor ICD Codes are billable

Billing for medical services and procedures often relies on specific codes, such as ICD-10, to accurately identify the diagnoses. Below are responses indicating whether commonly used ICD-10 codes for neuroendocrine tumors are billable:

• C25.0 - Malignant neoplasm of the head of the pancreas: Yes.
• C25.4 - Malignant neoplasm of the endocrine pancreas: Yes.
• C25.9 - Malignant neoplasm of pancreas, unspecified: Yes.
• C73 - Malignant neoplasm of the thyroid gland: Yes.
• C7A.0 - Islet cell tumor, malignant: Yes.
• C7B.00 - Malignant carcinoid tumor of the bronchus and lung, unspecified: Yes.
• D37.1 - Neoplasm of uncertain behavior of endocrine glands: Yes.
• D3A.9 - Benign neoplasm of endocrine gland, unspecified: Yes.
• D3A.1 - Benign carcinoid tumor: Yes.
• D3A.0 - Benign neoplasm of the stomach: Yes.

In general, whether malignant or benign, ICD-10 codes for neuroendocrine tumors are billable as they are crucial for insurance claims, reimbursement, and maintaining accurate medical records. 

However, it's essential to ensure that the specific guidelines and policies of the relevant healthcare payer or insurance provider use the codes. Always consult with coding experts, healthcare administrators, or billing professionals to ensure accurate and compliant coding practices.

Clinical information

• Neuroendocrine tumors are rare cancers originating from endocrine and nervous system cells.
• They can occur in various organs, including the pancreas, thyroid, lungs, and gastrointestinal tract.
• Clinical manifestations vary based on the tumor's location and hormone production.
• Common symptoms include abdominal pain, flushing, diarrhea, weight loss, and respiratory issues.
• It is often associated with hormonal hypersecretion, leading to distinct clinical syndromes such as insulinoma (insulin overproduction) or gastrinoma (gastrin overproduction).
• Arise from neuroendocrine cells and commonly affect the gastrointestinal tract and lungs.
• It may produce serotonin, causing carcinoid syndrome characterized by flushing, diarrhea, and wheezing.
• Imaging studies (CT, MRI, octreotide scans) help locate and characterize tumors.
• Blood tests measuring specific hormones aid in diagnosis and determining the extent of hormonal activity.
• Accurate coding is crucial for medical records, billing, and research.
• Common codes include C25.0 for pancreatic head tumors, C73 for thyroid gland tumors, and C7B.00 for bronchial and lung carcinoid tumors.
• Surgical resection is often the primary treatment, particularly for localized tumors.
• Somatostatin analogs, chemotherapy, and targeted therapies are used based on tumor characteristics.
• Prognosis varies widely depending on tumor type, grade, and stage.
• Regular imaging and hormonal assessments are essential for monitoring disease progression and treatment efficacy.
• Patient care involves collaboration among oncologists, endocrinologists, surgeons, and other specialists.
• Individualized treatment plans consider the tumor's biology and impact on hormonal function.

Synonyms include

• Carcinoid tumors
• Islet cell tumors
• Neuroendocrine neoplasms
• Pancreatic endocrine tumors
• Endocrine cell tumors
• Gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
• APUDomas (Amine Precursor Uptake and Decarboxylation tumors)